Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on monoclonal antibody therapies for serious viral infectious diseases, beginning with SARS-CoV-2. The Invivyd news feed on Stock Titan highlights company announcements about clinical development, regulatory milestones, commercial performance, financing activities, and pipeline expansion.
Recent Invivyd news has featured updates on PEMGARDA (pemivibart), the company’s investigational monoclonal antibody authorized under a U.S. FDA emergency use authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. The company reports quarterly PEMGARDA net product revenue and discusses uptake among healthcare providers caring for immunocompromised patients.
Investors also see frequent coverage of VYD2311, Invivyd’s vaccine-alternative monoclonal antibody candidate for COVID-19. News items describe FDA Fast Track designation, U.S. IND clearance, and the design of the Phase 3 DECLARATION trial within the broader REVOLUTION clinical program. Articles outline trial endpoints, intramuscular dosing regimens, and plans for pivotal data to support a potential Biologics License Application.
Beyond COVID-19, Invivyd’s news flow includes pipeline developments such as the selection of VBY329, a monoclonal antibody candidate for prevention of RSV infections in neonates, infants, and children, and discovery efforts targeting measles and other infectious diseases. Corporate news covers public offerings of common stock and pre-funded warrants, participation in healthcare conferences, and formation of the SPEAR Study Group to evaluate monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
By following the IVVD news page, readers can review Invivyd’s official press releases and related updates in one place, including earnings announcements, clinical trial progress, regulatory designations, and capital-raising transactions.
Invivyd (Nasdaq: IVVD) announced Chairman Marc Elia will speak at the POLITICO Health Care Summit on April 21, 2026 from 11:30 AM–12:00 PM ET. The session will discuss viral disease prevention and the role of monoclonal antibodies in advancing public health. The event will be live streamed 9:00 AM–1:00 PM ET.
Invivyd (Nasdaq: IVVD) reported a DECLARATION Phase 3 sample-size re-estimation that upsizes the trial by ~500 subjects and shifts expected top-line timing modestly to Q3 2026. The company aligned with the FDA on an initial pediatric study plan and advanced VMS063, a potent measles monoclonal antibody, toward IND-enabling work with target IND readiness in late 2026.
VMS063 shows low ng/mL and high-pg/mL neutralization across circulating measles lineages, is half-life extended, and targets a conserved measles F protein epitope.
Invivyd (Nasdaq: IVVD) launched a national education campaign, Antibodies for Any Body, in partnership with skier Lindsey Vonn on April 7, 2026. The campaign debut includes AntibodiesforAnyBody.com and an interactive Wellness Assessment to explain antibodies and lifestyle links to immune health.
The site offers accessible resources about antibody function and how sleep, nutrition, and activity may support immune protection; visitors are encouraged to consult their doctor about personalized habits.
Invivyd (Nasdaq: IVVD) announced inducement option grants made April 1, 2026, to 16 newly hired non-executive employees totaling 1,083,750 options under the Invivyd 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options carry a per-share exercise price of $1.33 (closing price on the grant date), vest over four years with 25% after one year and monthly vesting thereafter, and have a 10-year term, subject to plan terms and continuous service.
Invivyd (Nasdaq: IVVD) announced that Chief Scientific Officer Robert Allen, Ph.D. presented at the World Vaccine Congress Washington on March 30, 2026.
His talk, titled “Developing mAb Therapies that Keep Pace with Rapidly Evolving Viral Threats,” addressed monoclonal antibody scalability, access, economics, and strategies to manage virus variation, and highlighted Invivyd’s bespoke platform for vulnerable populations.
Invivyd (Nasdaq: IVVD) reported full-year 2025 net product revenue for PEMGARDA of $53.4M and Q4 2025 PEMGARDA revenue of $17.2M (Q4 YoY +25%). Cash and cash equivalents were $226.7M at year-end after >$200M raised in 2H 2025. DECLARATION Phase 3 enrollment is complete; top-line VYD2311 data expected mid-2026. FDA granted Fast Track for VYD2311 in Dec 2025. R&D expense fell to $38.3M and net loss narrowed to $52.5M for 2025.
Invivyd (Nasdaq: IVVD) appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer effective March 5, 2026. Dr. Mina brings expertise in infectious disease epidemiology, immunology, and clinical strategy, with more than 100 scientific publications and 10,000 citations.
His background includes academic posts at Harvard and leadership roles in diagnostics and digital health, and he will support Invivyd’s monoclonal antibody prevention and treatment pipeline.
Invivyd (Nasdaq: IVVD) will host a conference call on March 5, 2026 at 8:30 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a corporate update.
Interested parties can access a live webcast and analysts can join the Q&A via designated links; a recording will be posted to the company investor relations website shortly after the event.
Invivyd (Nasdaq: IVVD) granted inducement stock options to four newly hired non-executive employees on March 1, 2026, totaling 192,000 shares under the 2026 Inducement Plan.
The options carry a $1.69 exercise price (closing price Feb 27, 2026), vest over four years (25% after one year, then monthly), have a 10-year term, and were granted under Nasdaq Listing Rule 5635(c)(4).
Invivyd (Nasdaq: IVVD) published a peer-reviewed correlate-of-protection model that links serum monoclonal antibody levels to clinical protection against symptomatic COVID-19 across multiple Omicron-era variants.
The model, using CANOPY Phase 3 data for pemivibart, aligns with observed outcomes and predicts meaningful protection even at low antibody concentrations, supporting variant-agnostic assessment of COVID mAbs.